FDA panel supports ‘Viagra for women’

WASHINGTON — American women may soon have access to a controversial libido-enhancing pill dubbed “pink Viagra” after a government panel on Thursday gave its backing to what would be the first FDA-approved drug for the treatment of female sexual dysfunction.

In an 18-6 vote, a panel of Food and Drug Administration experts recommended allowing the experimental drug, flibanserin, to be sold in the U.S. as long as certain safety precautions are taken to minimize potential side effects, which include low blood pressure, dizziness and fainting.

Some say drugs such as flibanserin could enhance women’s sex lives in the same way erectile-dysfunction medications have improved men’s. But experts in female sexuality scoff at the notion that a 100-milligram pill, taken daily at bedtime, will turn women’s sexual desires on with the ease of flipping a light switch. In clinical trials, the drug had a small but measurable effect.

The vote is a major victory for the drug’s owner, North Carolina-based Sprout Pharmaceuticals. Two previous attempts to win approval of flibanserin before the same FDA committee failed amid questions about the drug’s risks and efficacy. Though a final decision will be made in the coming months by FDA Commissioner Stephen Ostroff, the panel’s recommendation is likely to weigh heavily.

“I think it’s a major step forward in better understanding of women’s sexuality and better understanding of women being able to take control of their own sexuality in a healthy way,” said National Organization for Women President Terry O’Neill.

The debate over developing and marketing a pill to treat women’s sexual problems has run for years as scientists and pharmaceutical companies rushed to duplicate the success of the blockbuster drug Viagra.

Supporters of flibanserin complained that the FDA has approved several sexual-dysfunction drugs for men, including Viagra, but not a single one for the millions of American women suffering from low libido. Critics accused the agency of a sexist double standard.

Opponents of the drug argue that pharmaceutical companies are seeking to profit by medicalizing what they say is often an emotional or relationship issue.

“We keep getting this narrative from the drug company and the patients that these women are unfixable without the drug,” said Thea Cacchioni, women’s studies professor at the University of Victoria in Canada, adding that research suggests non-pharmaceutical solutions could address some of the same issues.

If ultimately approved, flibanserin would be the first nonhormonal treatment for “hypoactive sexual desire disorder,” or HSDD, in premenopausal women. The condition afflicts some 4.8 million premenopausal women, but physicians have had essentially nothing to offer them, according to Sprout.

While Viagra and similar drugs work by increasing blood flow to create an erection, flibanserin works on key chemicals in the brain to stimulate a woman’s sexual desire.

Critics are still urging the FDA to reject the drug, citing its side effects and lackluster results.

Chief among the safety concerns is evidence from clinical trials showing that some women taking flibanserin are at higher risk of low blood pressure and fainting. Members of the panel were particularly concerned about the risk when flibanserin is taken with alcohol.

Although members of the panel suggested a litany of additional safety precautions to accompany the drug, the final decision lies with the FDA.

In clinical trials, flibanserin was found to somewhat increase the number of “sexually satisfying events” women reported to researchers. On average, women taking the drug reported up to one more such event per month, compared with women taking a placebo.

At a hearing Thursday, supporters – including doctors and clinical trial participants – defended the drug, saying even small improvements were important to patients.

A couple of years after she got remarried, Amanda Parrish, 52, of Brentwood, Tenn., noticed she no longer initiated sexual contact with her husband, Ben. “A wall went up between us,” she said in an interview.

About a year later, she found an HHSD pamphlet in her doctor’s office and joined the flibanserin trial.

“I personally was elated that there was a legitimate medical reason for what was going on,” she said. After taking the drug, her relationship quickly improved, she said. But since the trial ended, she said, the condition has returned, causing stress and anxiety.

She said she left the Thursday vote elated. “I actually said to them as we left today, ‘Can we all get some to take home tonight?’ “

Sally Greenberg, executive director of the National Consumers League, said she supported approval because without an FDA-certified drug, women might turn to unregulated or dangerous substitutes. “There is a huge unmet need for women’s low libido,” Greenberg said before the vote.

The FDA faced a strong public campaign, partly organized by Sprout, in support of the drug, including websites such as EvenTheScore.org and WomenDeserve.org, characterizing the debate as one of gender equality and fairness.

“If you vote no today based on this risk, it would signal that you do not believe that HSDD warrants treatment at all,” said Anita Clayton, a University of Virginia professor who has worked as a consultant for Sprout but said she had no financial stake in the drug. “Maybe the message is that you do not trust women with HSDD not to drink to intoxication, or you just don’t trust women.”

The drug was developed by German pharmaceutical company Boehringer Ingelheim, which first asked the FDA in 2010 to consider approval. An advisory panel voted 10-1 to recommend against it, citing scant evidence of the drug’s effectiveness. Sprout Pharmaceuticals later acquired the drug from Boehringer.

Talk to us

> Give us your news tips.

> Send us a letter to the editor.

> More Herald contact information.

More in Local News

Olivia Vanni / The Herald 
The Mukilteo Lighthouse. Built in 1906, it’s one of the most iconic landmarks in Snohomish County.
The Mukilteo Lighthouse. Built in 1906, it’s one of the most iconic landmarks in Snohomish County. (Olivia Vanni / The Herald)
Mukilteo mayor vetoes council-approved sales tax

The tax would have helped pay for transportation infrastructure, but was also set to give Mukilteo the highest sales tax rate in the state.

Marysville Mayor Jon Nehring gives the state of the city address at the Marysville Civic Center on Wednesday, Jan. 31, 2024, in Marysville, Washington. (Ryan Berry / The Herald)
Marysville council approves interim middle housing law

The council passed the regulations to prevent a state model code from taking effect by default. It expects to approve final rules by October.

x
State audit takes issue with Edmonds COVID grant monitoring

The audit report covered 2023 and is the third since 2020 that found similar issues with COVID-19 recovery grant documentation.

Bothell
Bothell man pleads guilty to sexual abuse of Marysville middle schoolers

The man allegedly sexually assaulted three students in exchange for vapes and edibles in 2022. His sentencing is set for Aug. 29.

Larsen talks proposed Medicaid cuts during Compass Health stop in Everett

Compass Health plans to open its new behavioral health center in August. Nearly all of the nonprofit’s patients rely on Medicaid.

District 2 candidates differ in public safety approach

Incumbent Paula Rhyne is facing challenger Ryan Crowther. The third candidate, Jonathan Shapiro, is no longer seeking the seat.

From left to right, Edmonds City Council Position 3 candidates Joseph Ademofe, Alex Newman and Erika Barnett.
Amid budget crisis, Edmonds City Council candidates talk revenue, affordability

Three newcomers are facing off for Position 3 on the council, currently held by council President Neil Tibbott.

Community members gather for the dedication of the Oso Landslide Memorial following the ten-year remembrance of the slide on Friday, March 22, 2024, at the Oso Landslide Memorial in Oso, Washington. (Ryan Berry / The Herald)
The Daily Herald garners 6 awards from regional journalism competition

The awards recognize the best in journalism from media outlets across Alaska, Idaho, Montana, Oregon and Washington.

Everett
Everett approves new fines for non-emergency lifts

The fire department will only issue fines for non-emergency lift assists at licensed care facilities, not for individuals at home calling 911.

Guns for sale at Caso’s Gun-A-Rama in Jersey City, New Jersey, which has been open since 1967. (Photo by Aristide Economopoulos/New Jersey Monitor)
After suing, WA gets carveout from Trump administration plan to return gun conversion devices

The Trump administration has agreed to not distribute devices that turn semi-automatic… Continue reading

The Wild Horse Wind and Solar Facility about 16 miles east of Ellensburg in central Washington is part of Puget Sound Energy’s clean energy portfolio. (Courtesy of Puget Sound Energy)
Megabill’s elimination of tax credits for clean energy projects could cost WA $8.7 billion

Washington households could see electricity costs increase $115 per year by 2029; 21,800 workers could lose their jobs by 2030, analysts say.

Everett mayor candidates focus on affordability, city budget in costly race

As incumbent Cassie Franklin seeks a third term in office, three candidates are looking to unseat her.

Support local journalism

If you value local news, make a gift now to support the trusted journalism you get in The Daily Herald. Donations processed in this system are not tax deductible.